Pituitary and adrenal function in normal women after treatment with Lergotrile mesylate.
We studied the effects of a dopaminergic agonist, 2-chloro-6-methyl-ergoline-8-beta-acetonitrile methanesulfonate (LERGOTRILE mesylate), on the pituitary and adrenal function of five normal women. No changes were observed in basal serum luteinizing hormone (LH), follicle-stimulating hormone (FSH), growth hormone (GH) and cortisol levels, in LH and FSH levels after luteinizing hormone-releasing hormone (LH-RH) stimulation, or in GH and cortisol levels during insulin-induced hypoglycemia. Lergotrile treatment produced a fall in basal prolactin and thyrotropin (TSH) levels and there was dissociation in the responses of the women to thyrotropin-releasing hormone: attenuation of TSH release, but retention of prolactin release.